NCT06458595View on ClinicalTrials.gov

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

December 28, 2026

Conditions

Age-related Macular Degeneration

Interventions

DRUG

KH658

KH658 Ophthalmic Injection

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors

lead

Chengdu Origen Biotechnology Co., Ltd.

INDUSTRY

NCT06458595 - Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) | Biotech Hunter | Biotech Hunter